CARNEGIE-MELLON UNIVERSITY

• GEORGE WASHINGTON UNIVERSITY (THE)

  UEI ECR5E2LU5BL6

  $402.7K

  Subcontractor to this prime · 1 sub-award · latest Apr 28, 2026

  • Department of the Army
  • “HYDRAULIC, CHEMICAL, AND MICROBIOLOGICAL EFFECTS ON THE PERFORMANCE OF IN-SITU ACTIVATED CARBON SORPTIVE BARRIER FOR PFAS REMEDIATION IN COASTAL SITES”
• HONEYWELL FEDERAL MANUFACTURING & TECHNOLOGIES, LLC

  UEI DMEGBYTVBQS5

  $141.3K

  Subcontractor to this prime · 1 sub-award · latest Jan 18, 2024

  • Department of Energy
  • “R&D”

• SYNAPSE SYMPHONY INC.

  UEI CX1VMME52NH4 · not in the directory yet

  $234.9K

  Subcontracted by this company · 1 sub-award · latest May 27, 2025

  • Defense Advanced Research Projects Agency
  • “IN THE EMBEDDED ENTREPRENEURSHIP INITIATIVE (EEI) PROGRAM, OUR FIRM WILL PLAY A CRUCIAL AND MULTIFACETED ROLE IN TRANSFORMING SHARPFOCUS TECHNOLOGY INTO A VIABLE COMMERCIAL PRODUCT. FOR THIS WE WILL FORM A SYNERGISTIC PARTNERSHIP WITH CMU AND FOSTER A COLLABORATIVE NETWORK THAT ACCELERATES THE DEVELOPMENT AND DEPLOYMENT OF SHARPFOCUS TECHNOLOGY. ONCE THE EE AND FDA CONSULTANT WILL BE HIRED, A STRATEGIC PLANNING WILL BE MADE, AND WE WILL TAKE LEAD ON FILING NEW IPS RELATED TO THE TECHNOLOGY AND LICENSING THE EXISTING IP RIGHTS FROM CMU. ALONG WITH CMU, WE WILL LEAD THE PROCESS OF IDENTIFICATION AND PENETRATION OF THE NICHE MARKETS, CREATE STRATEGIES FOR SCALING SHARPFOCUS TO BROADER MARKETS, AND ENGAGE DIRECTLY WITH END-USERS AND CUSTOMERS TO REFINE OUR TECHNOLOGY BASED ON REAL-WORLD FEEDBACK. THIS CUSTOMER-CENTRIC APPROACH WILL ENSURE THAT OUR APPROACH MEETS ACTUAL MARKET NEEDS AND DEMANDS. WE WILL REPRESENT OUR TECHNOLOGY AT DIFFERENT PLATFORMS LIKE CONFERENCES, ASSOCIATION WORKSHOPS ETC. TO ENSURE PROPER REIMBURSEMENT AND COVERAGE FOR OUR NEW DEVICE/PROCEDURE, WE WILL UNDERTAKE A MULTI-PRONGED APPROACH. FIRST, WE WILL COLLABORATE WITH MEDICAL SPECIALISTS AND RELEVANT SOCIETIES TO ESTABLISH A CATEGORY III CPT CODE, WHICH IS A CRUCIAL STEP IN THE REIMBURSEMENT PROCESS. SIMULTANEOUSLY, WE WILL COMPILE REAL- WORLD EVIDENCE FROM CLINICAL STUDIES, DEMONSTRATING THE DEVICE'S EFFICACY, SAFETY, AND COST- EFFECTIVENESS COMPARED TO EXISTING PAIN TREATMENTS. THIS EVIDENCE WILL BE A VITAL COMPONENT IN OUR VALUE PROPOSITION TO PAYERS. ARMED WITH THIS COMPELLING EVIDENCE, WE WILL PROACTIVELY ENGAGE WITH COMMERCIAL PAYERS AND MEDICARE CONTRACTORS. OUR GOAL WILL BE TO PRESENT A PERSUASIVE CASE FOR COVERING THE NEW DEVICE, HIGHLIGHTING ITS VALUE PROPOSITION AND THE POTENTIAL BENEFITS IT OFFERS TO PATIENTS AND THE HEALTHCARE SYSTEM AS A WHOLE. FURTHER WITH THE GUIDANCE OF FDA CONSULTANT REGULATORY PATHWAYS WILL BE EXPLORED AND AN INITIATIVE WILL BE TAKEN TO START THE PROCEDURE BY SC”

Agencies generally may not award to excluded parties, and primes may not subcontract with them above the threshold in FAR 52.209-6 (except COTS items) without a compelling reason reported to the contracting officer (FAR 9.405, 9.405-2). Some exclusion types apply only to specific programs: read the record on SAM.gov.

No confirmed match on the Consolidated Screening List (screened Nov 13, 2026).

The list combines Commerce, State and Treasury export-control and sanctions lists. A “no match” result is a name-and-address screen, not an export-compliance determination.